NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Clinical Trials
28 trialsNCT00532155 2025-09-10
VITAL
Sanofi
Phase 3 Completed
NCT03710564 2023-01-30
MERLIN
Novartis
Phase 3 Terminated
NCT00794417 2020-12-10
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT01571284 2018-04-17
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Sanofi
Phase 3 Completed
NCT01882868 2017-03-14
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Sanofi
Phase 2 Completed
NCT01670721 2016-11-28
AFEQT
Sanofi
Phase 3 Completed
NCT01661270 2016-10-18
AFLAME
Sanofi
Phase 3 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00574275 2016-06-07
VANILLA
Sanofi
Phase 3 Terminated
NCT00851084 2016-06-07
AFFIRM
Sanofi
Phase 2 Completed
NCT00036946 2016-06-03
VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00045266 2016-06-03
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00082823 2016-06-03
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00083213 2016-06-03
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00644124 2016-05-06
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
Sanofi
Phase 1 Completed
NCT00876044 2016-05-05
QUTIE
Sanofi
Phase 1 Completed
NCT01955629 2016-04-18
AMOR
Sanofi
Phase 1/2 Terminated
NCT01688960 2015-03-17
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed
NCT02085005 2014-11-18
Drop and Go
Sanofi
Phase 2 Withdrawn
NCT00545246 2013-10-16
A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients
Sanofi
Phase 1 Completed
NCT00396591 2013-01-10
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
Phase 2 Completed
NCT00327444 2013-01-01
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
Phase 2/3 Completed
NCT00284141 2012-12-10
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
Sanofi
Phase 2 Completed
NCT00921661 2012-11-09
Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
Sanofi
Phase 1 Completed
NCT00561470 2012-09-28
VELOUR
Sanofi
Phase 3 Completed
NCT01148615 2012-01-13
A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors
Sanofi
Phase 1 Completed
NCT00479076 2011-01-26
A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients
Sanofi
Phase 1 Completed